欧康维视生物-B:OT-802 III期临床试验授权获批

Core Viewpoint - The announcement highlights that the company has received approval from the National Medical Products Administration for the Phase III clinical trial of its self-developed product OT-802, which is indicated for the treatment of presbyopia [1] Group 1 - The product OT-802 is a hydrochloride solution of pilocarpine eye drops [1] - Preclinical studies indicate that OT-802 has a rapid onset of action and high safety profile [1] - The company plans to initiate the Phase III clinical trial of OT-802 as soon as possible [1]